CorMedix Inc
NASDAQ:CRMD
Operating Margin
CorMedix Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
CorMedix Inc
NASDAQ:CRMD
|
769.9m USD |
18%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
746.7B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
374.7B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
191.1B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
160.7B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
211.1B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
185.4B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
144.9B USD |
27%
|
CorMedix Inc
Glance View
CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on CorMedix Inc's most recent financial statements, the company has Operating Margin of 17.5%.
You don't have any saved screeners yet